Screening tests for hepatocellular carcinoma.
Screening tests for hepatocellular carcinoma.
复制标题
DOI：
10.1016/j.cld.2004.12.006
复制
发表时间：
2005-05-01
影响因子：
5.1
通讯作者：
Marrero, Jorge A
中科院分区：
文献类型：
--
作者：
Marrero, Jorge A
肝细胞癌的发病率在全球范围内呈上升趋势。肝细胞癌符合疾病从筛查或监测中受益的标准：它是一个重要的健康问题；那些患有肝硬变的人是监测的目标；如果及早诊断，可以接受治疗；使用甲胎蛋白和超声波的监测已被证明是具有成本效益的；卫生保健专业人员广泛实施监测并被患者接受；存在标准化的召回程序；筛查测试必须在接受筛查的人群中达到可接受的准确性水平。后一点是肝癌监测的主要局限性。在这篇综述中，我们将讨论目前可用于肝细胞癌监测的检测方法。
The incidence of hepatocellular carcinoma (HCC) is rising throughout the world. HCC meets the criteria for which a disease benefits from screening or surveillance: it is an important health problem; those with cirrhosis are the targets for surveillance; there is acceptable treatment if diagnosed early; surveillance using alpha-fetoprotein and ultrasound has been shown to be cost effective; surveillance is widely implemented by health care professionals and accepted by patients; standardized recall procedures exists; and the screening tests must achieve an acceptable level of accuracy in the population undergoing screening. The latter point is the main limitation of surveillance for HCC. In this review we will discuss the currently available tests for the surveillance of HCC.